Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: infi.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/18/2021 | $9.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $6.00 | Neutral → Overweight | JP Morgan |
| 7/28/2021 | $4.00 → $14.00 | Equal-Weight → Overweight | Wells Fargo |
| 7/7/2021 | $7.00 | Buy | B. Riley Securities |
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init
Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023, at 10:00 a.m. Eastern Time: Dear Fellow MEI Shareholders, We have extended the opportunity for shareholders to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. If you haven't voted yet, you can still do so today. Through this transaction, we are creating a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI") at the special meeting of Infinity stockholders held earlier today (the "Special Meeting"). The transaction remains subject to approval by MEI stockholders. Final voting results for the Special Meeting will be disclosed on Form 8-K filed by Infinity with the U.S. Securities and Exchange Commission. About Infinit
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the upcoming special meeting on July 14, 2023. MEI issued the following statement: With the special meeting just days away, now is the time for MEI shareholders to vote FOR our pending Infinity transaction. As a reminder, Independent leading proxy advisory firms, ISS and Glass Lewis, both recommend that MEI shareholders vote FOR the Infinity transaction. In making their recommendations, both ISS and Glass Lewis recognize the strategic benefits of our combination with Infinity. MEI sh
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced further design features of its Phase 2 MARIO-8 study in SCCHN. The adaptive design of the MARIO-8 study is intended to optimize the dose of the oral drug candidate, eganelisib, in combination with the standard dose of pembrolizumab, in 40-70 patients in Part A of the study. The dose optimization phase of the study will evaluate two dose regimens of eganelisib; a 30mg regimen, dosed daily for two out of every three weeks, and a 20mg regimen, with continuous daily dosing. The compan
Glass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the upcoming special meeting on July 14, 2023. The Company noted that leading proxy advisory firm Glass Lewis joined ISS in recommending that shareholders vote FOR the transaction. MEI issued the following statement: MEI shareholders have the opportunity to participate in the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline of thr
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that leading independent proxy advisor Institutional Shareholder Services Inc. ("ISS") has recommended that Infinity stockholders vote FOR the merger with MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"). ISS is an independent proxy advisory firm whose clients include many of the world's leading institutional investors, and who rely on ISS's objective and impartial analysis to make important voting decisions. "We are pleased to receive ISS's independent recommendation to I
Affirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that MEI Pharma shareholders vote "FOR" the Company's pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the upcoming special meeting on July 14, 2023. MEI issued the following statement in response to the report: We are pleased that ISS
Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno
– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page
– Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 – – MARIO-3 triple negative breast cancer (TNBC) data update on track by year end – – Further eganelisib clinical development stage gated on potential partnership – – Increased 2022 year-end cash guidance with runway extended into 2024 – – Investor conference call to be held today at 4:30 PM EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarte
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022. Conference Call & Webcast Details Date: Tuesday, August 9th Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/ci3bx9cc Toll Free: (800) 715-9871 International: (646) 307-1963 ID Number: 303241 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website a
– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer (TNBC) expected to initiate by year-end 2022 – – MARIO-P, a clinical program designed to expand eganelisib development in additional solid tumor indications, is planned to start in 3Q2022 – – Investor conference call to be held May 3, 2022 at 4:30pm EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2022 financial results and provided a corporate update. "We are pleased t
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022. Conference Call & Webcast Details Date: Tuesday, May 3rd Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/prmegw6b Toll Free: (877) 316-5293 International: (631) 291-4526 ID Number: 6618485 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website
– MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 – – MARIO-P, a study designed to expand eganelisib development in additional solid tumor indications, expected to initiate on a rolling basis in 3Q 2022 – – Ended 2021 with ~ $81 million of cash and cash equivalents – – Mr. Sujay Kango appointed to Infinity Board of Directors – – Investor conference call to be held today at 4:30 pm EDT – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogram
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, March 29th, 2022 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2021. Conference call & Webcast Details Date: Tuesday, March 29th Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/gpu89sxf Toll Free: (877) 316-5293 International: (631) 291-4526 ID Number: 7567637 A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website at www.infi.com and will be available
– Encouraging data for eganelisib in both PD-L1(-) and PD-L1(+) mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark – – Updated mTNBC data to be presented at San Antonio Breast Cancer Symposium – – Encouraging data for eganelisib in mUC patients, with a 7.5 month extension of overall survival versus control arm – – Strengthened leadership team with Chief Scientific Officer, Chief Medical Officer and Board appointments – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company") today announced its third quarter 2021 financial results and provided a corporate update on eganelisib, its potentially first-in-class, oral, immuno-oncology
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
3 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00
JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00
Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously
B. Riley Securities resumed coverage of Infinity Pharmaceutical with a rating of Buy and set a new price target of $7.00
Truist initiated coverage of Infinity Pharmaceutical with a rating of Buy and set a new price target of $12.00
Wells Fargo reiterated coverage of Infinity Pharmaceuticals with a rating of Equal-Weight and set a new price target of $4.00 from $2.00 previously
Piper Sandler initiated coverage of Infinity Pharmaceuticals with a rating of Overweight and set a new price target of $7.00
Piper Sandler initiated coverage of Infinity Pharmaceuticals with a rating of Overweight and set a new price target of $7.00
B. Riley resumed coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $4.50 previously
Oppenheimer reiterated coverage of Infinity Pharmaceuticals with a rating of Outperform and set a new price target of $9.00 from $5.50 previously
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
10-Q - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
DEFA14A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
DEFA14A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)